SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Tirzepatide use vs placebo was associated with slower decline in eGFR among patients with prediabetes and obesity or overweight.

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

Measuring insulin levels in saliva is a non-invasive way to determine if someone is at risk of developing type 2 diabetes and ...

Medical professionals observe that GLP-1 medications like Ozempic show promise for treating rheumatoid arthritis alongside other inflammatory conditions.

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Biotechs investigate mitochondria-targeting drugs to claim a share in the weight loss drug market dominated by GLP-1RAs.

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Note that some links may require registration or subscription. Justin Timberlake said he has been diagnosed with Lyme disease ...

Bristol-Myers Squibb Company beats revenue forecasts & raises 2025 guidance. Click for key BMY catalysts, risks, and outlook ...

A doctor has issued a warning to people who use weight loss jabs over the 'golden dose'. The use of GLP-1 medication, such as ...

Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and ...